BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2016

View Archived Issues

FDA grants orphan drug status to BioVie's BIV-201 for ascites

Read More

Bristol-Myers Squibb initiates phase I/II trial of BMS-986183 in advanced hepatocellular carcinoma

Read More

GSK initiates phase II trial of GSK-2982772 in psoriasis

Read More

Oncology Venture incorporates oncology therapeutics spin-out 2X Oncology in U.S.

Read More

AdAlta signs manufacturing agreement for AD-114

Read More

FDA clears IND for phase I trial of Cantrixil in ovarian cancer

Read More

RespireRx announces preliminary topline data from phase IIa trial of CX-1739

Read More

Horizon Pharma to acquire Raptor Pharmaceutical

Read More

GlaxoSmithKline submits MAA for sirukumab in rheumatoid arthritis

Read More

Novel RBM20 gene mutation linked to left ventricular noncompaction cardiomyopathy

Read More

FDA gives fast track designation to niraparib, Tesaro begins rolling NDA submission

Read More

SK Biopharmaceuticals patents mGlu5 receptor PAMs

Read More

First patient dosed in Xencor's phase I study of Xmab-14045

Read More

Sunshine Lake Pharma and Calitor Sciences disclose PI3Kdelta inhibitors

Read More

Bayer Pharma describes anticancer agents

Read More

Bristol-Myers Squibb reports development of NS5B inhibitors

Read More

Amplyx Pharmaceuticals doses first patients in phase I study of antifungal agent

Read More

Janssen-Cilag submits MAA to EMA for darunavir-based single tablet regimen

Read More

MacroGenics regains rights to MGD-010 from Takeda

Read More

VCAM1 and ANGPTL4 show promise as successful pleurodesis biomarkers

Read More

Repros Therapeutics submits MAA for enclomiphene

Read More

Mutations in PRODH2 could be genetic cause of hydroxyprolinemia

Read More

PNPLA4 identified as novel causative gene for mitochondrial respiratory chain disorders

Read More

Janssen applies for emergency use assessment and listing of Ebola prime-boost vaccine regimen

Read More

FDA clears Angionetics' phase III study of Generx gene therapy

Read More

UD-009 shows efficacy in pulmonary fibrosis model

Read More

Interim topline data from phase Ib study of GED-0301 in active Crohn's disease

Read More

Brain penetration, effects on disease seen with SBC-103 in mucopolysaccharidosis IIIB

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing